Soluble Urokinase Plasminogen Activator Receptor (SuPAR) Analysis for Diagnosis of Periprosthetic Joint Infection

被引:0
|
作者
Klim, Sebastian M. [1 ]
Prattes, Juergen [2 ]
Amerstorfer, Florian [1 ]
Niedrist, Tobias [3 ]
Zurl, Christoph [2 ]
Stradner, Martin [4 ]
Dreo, Barbara [4 ]
Glehr, Gunther [5 ]
Leithner, Andreas [1 ]
Glehr, Mathias [1 ]
Reinbacher, Patrick [1 ]
Sadoghi, Patrick [1 ]
Hauer, Georg [1 ]
机构
[1] Med Univ Graz, Dept Orthopaed & Trauma, A-8036 Graz, Austria
[2] Med Univ Graz, Dept Internal Med, Div Infect Dis, A-8036 Graz, Austria
[3] Med Univ Graz, Clin Inst Med & Chem Lab Diagnost, A-8036 Graz, Austria
[4] Med Univ Graz, Dept Internal Med, Div Rheumatol & Immunol, A-8036 Graz, Austria
[5] Univ Hosp Regensburg, Dept Surg, D-93053 Regensburg, Germany
来源
ANTIBIOTICS-BASEL | 2024年 / 13卷 / 02期
关键词
suPAR; joint infection; synovia; inflammation; diagnostic biomarker; PLASMA; INFLAMMATION; ARTHRITIS; BIOMARKER; SEPSIS; LEVEL;
D O I
10.3390/antibiotics13020179
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Soluble urokinase plasminogen activator receptors (suPARs) are a biomarker for inflammatory diseases. This study aims to investigate its diagnostic properties regarding periprosthetic joint infections (PJI). This retrospective cohort study included adult patients who underwent joint puncture for suspected PJI. The presence of PJI was determined according to the criteria of the European Bone and Joint Infection Society (EBJIS). Laboratory study analyses included the determination of white blood cells (WBC) in whole blood, C-reactive protein (CRP) in blood plasma, and suPAR in both blood plasma and synovial fluid. Appropriate diagnostic cut-off values were identified utilizing Youden's J, and their diagnostic performance was determined by calculating the positive (PPV) and negative predictive value (NPV) for each marker. Sixty-seven cases were included in the final analysis. Forty-three samples (64%) were identified as periprosthetic joint infection (PJI) and twenty-four specimen (36%) were PJI negative cases. The PPV and NPV were 0.80 and 0.70 for synovial suPAR, 0.86 and 0.55 for CRP, 0.84 and 0.31 for WBC and 1.00 and 0.31 for plasma suPAR. Synovial suPAR showed a solid diagnostic performance in this study and has the potential to be an alternative or complementary biomarker for PJI. Further investigations in larger patient collectives are indicated.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Soluble Urokinase Plasminogen Activator Receptor (suPAR) in Autoimmune Rheumatic and Non Rheumatic Diseases
    Manfredi, Mariangela
    Van Hoovels, Lieve
    Benucci, Maurizio
    De Luca, Riccardo
    Coccia, Carmela
    Bernardini, Pamela
    Russo, Edda
    Amedei, Amedeo
    Guiducci, Serena
    Grossi, Valentina
    Bossuyt, Xavier
    Perricone, Carlo
    Infantino, Maria
    JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (04):
  • [2] Evaluation of plasma soluble urokinase plasminogen activator receptor (SuPAR) levels in ulcerative colitis
    Yilmaz, Huriye Erbak
    Aksun, Saliha
    Gunay, Sueleyman
    Elmali, Ferhan
    Cekic, Cem
    ARAB JOURNAL OF GASTROENTEROLOGY, 2023, 24 (03) : 175 - 179
  • [3] Plasma soluble urokinase plasminogen activator receptor (suPAR) levels in ankylosing spondylitis
    Toldi, Gergely
    Szalay, Balazs
    Beko, Gabriella
    Kovacs, Laszlo
    Vasarhelyi, Barna
    Balog, Attila
    JOINT BONE SPINE, 2013, 80 (01) : 96 - 98
  • [4] Associations between soluble urokinase plasminogen activator receptor (suPAR) concentration and psychiatric disorders - A systematic review and meta-analysis
    Murphy, Jennifer
    Zierotin, Anna
    Mongan, David
    Healy, Colm
    Susai, Subash R.
    Donoghue, Brian O. '
    Clarke, Mary
    O'Connor, Karen
    Cannon, Mary
    Cotter, David R.
    BRAIN BEHAVIOR AND IMMUNITY, 2024, 120 : 327 - 338
  • [5] Usefulness of soluble urokinase plasminogen activator receptor (suPAR) as an inflammatory biomarker in obese children
    Kosecik, Mustafa
    Dervisoglu, Pinar
    Koroglu, Mehmet
    Isguven, Pinar
    Elmas, Bahri
    Demiray, Tayfur
    Altindis, Mustafa
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 228 : 158 - 161
  • [6] Plasma soluble urokinase plasminogen activator receptor (suPAR) levels in systemic lupus erythematosus
    Toldi, Gergely
    Szalay, Balazs
    Beko, Gabriella
    Bocskai, Marta
    Deak, Magdolna
    Kovacs, Laszlo
    Vasarhelyi, Barna
    Balog, Attila
    BIOMARKERS, 2012, 17 (08) : 758 - 763
  • [7] The role of soluble urokinase plasminogen activator receptor (suPAR) in the diagnostics of diabetic foot infection
    Aslan, Sevinc
    Demirdal, Tuna
    Erbak, Huriye
    Aslan, Cem
    INFECTIOUS DISEASES, 2020, 52 (02) : 107 - 113
  • [8] Soluble urokinase-type plasminogen activator receptor (suPAR) as new biomarker of the prosthetic joint infection: Correlation with inflammatory cytokines
    Galliera, Emanuela
    Drago, Lorenzo
    Marazzi, Monica Gioia
    Romano, Carlo
    Vassena, Christian
    Romanelli, Massimiliano M. Corsi
    CLINICA CHIMICA ACTA, 2015, 441 : 23 - 28
  • [9] Plasma Soluble Urokinase Plasminogen Activator Receptor (suPAR) and CKD Progression in Children
    Weidemann, Darcy K.
    Abraham, Alison G.
    Roem, Jennifer L.
    Furth, Susan L.
    Warady, Bradley A.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2020, 76 (02) : 194 - 202
  • [10] Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation
    Rasmussen, Line Jee Hartmann
    Petersen, Jens Emil Vang
    Eugen-Olsen, Jesper
    FRONTIERS IN IMMUNOLOGY, 2021, 12